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ABSTRACT 
Backgrounds Early onset dementia (EOD) is defined as functionally relevant cognitive decline with 
age of onset less than 65 years. The aim of this study was to investigate the utility of the recently 
validated third version of the Addenbrooke’s Cognitive Examination (ACE-III) in predicting dementia 
diagnoses in EOD. Methods ACE-III scores of EOD patients were compared to those of healthy 
controls (HC) and individuals with subjective memory impairment (SMI). Results The study included 
71 EOD patients: Alzheimer’s disease (n=31); Primary Progressive Aphasia (n=11), behavioural-
variant frontotemporal dementia (bvFTD, n=18); and Posterior Cortical Atrophy (n=11), 28 HC, and 
15 SMI. At a cut-off score of 88/100, the ACE-III displayed high sensitivity and specificity in 
distinguishing EOD from HC (91.5% and 96.4%) and SMI (91.5% and 86.7%). Conclusions The 
ACE-III is a reliable cognitive screening tool in EOD.  
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INTRODUCTION 
Early onset dementia (EOD) is defined as functionally impairing cognitive decline arising 
before the age of 65 years.1 Aetiologies are diverse; although the most common presentations 
are secondary to Alzheimer’s disease, and frontotemporal dementia. Subjective cognitive 
impairment, relating to heightened awareness of normal symptoms or health-related anxiety, 
is an important differential diagnosis.2  
Early and accurate diagnosis of dementia reduces uncertainty and unnecessary investigations, 
and allows more accurate prognostication. Crucially, it also facilitates timely introduction of 
symptomatic therapies and recruitment of well-characterised patients into clinical trials.3 
 
The Addenbrooke’s Cognitive Examination (ACE) is a cognitive test widely used for 
diagnostic screening, and longitudinal follow-up of cognitive decline in dementia. A third 
version of this tool (ACE-III) was designed to address weaknesses identified in previous 
versions and has been validated.4 The instrument’s  utility has been recently investigated in 
patients over 75.5 This study aimed to investigate the diagnostic utility of the ACE-III in 
EOD. 
METHODS  
Patients with EOD were identified from the Edinburgh Cognitive Disorders Clinic Diagnosis 
Audit Research and Treatment (CDC-DART) Register at the Anne Rowling Regenerative 
Neurology Clinic, University of Edinburgh. We identified 71 consecutive patients fulfilling 
consensus clinical diagnostic criteria for specific dementia diagnoses,6-8 including, 
Alzheimer‘s disease (AD, n=31), behavioural-variant frontotemporal dementia (bvFTD, 
n=18), primary progressive aphasia (PPA, n=11) and posterior cortical atrophy (PCA, n=11) 
presenting between December 2013 and December 2014. We also identified patients 
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attending the clinic with subjective memory impairment (SMI, n=15). Diagnoses were made 
following multi-professional clinical assessments (neurology, psychiatry, neuropsychology) 
incorporating where appropriate cerebrospinal fluid biomarkers and neuroimaging. The 
majority of patients (90.3%) had both structural (1.5T MRI, or CT if MRI contraindicated/not 
tolerated) and 99mTc-HMPAO SPECT brain imaging as part of routine evaluation.9  SMI was 
defined as the presence of non-progressive symptoms (including on longitudinal follow up) 
whereby degenerative dementias have been excluded in the context of a high index of 
suspicion by a psychiatrist and neurologist that symptoms represent a heightened awareness 
of normal bodily symptoms or related to affective symptoms.. 
Patients were excluded if age at onset was older than 65, if a non-neurodegenerative cause for 
cognitive impairment was identified, or if there was diagnostic uncertainty. 
ACE-III was conducted as part of routine clinical workup for all patients. The ACE-III was 
also undertaken in a cohort of healthy controls (n=28) recruited from the University of 
Edinburgh Department of Psychology research subject pool.  
All participants gave informed consent for their data to be used for research as part of the 
CDC-DART register (approved by the Scotland-A Research Ethics committee). Recruitment 
of healthy controls was approved by the Department of Psychology, University of Edinburgh 
Ethics Committee.  
STATISTICAL METHODS  
Between-groups comparisons were carried out using one-way-ANOVA with post- hoc 
Bonferroni-corrected pairwise comparisons. Standard methods were used to transform 
variables in case of non-normality. Proportions were expressed in percentages and 
comparisons were made using Pearson x2 test.  
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Correlational analyses were carried out using Spearman Rank correlation coefficient. 
Receiver operating characteristic curve (ROC) analyses was used to identify optimum ACE-
III cut-off to distinguish patients from controls.  
 
All data was analysed using SPSS statistics (version 21).Cut-off for statistical significance 
was set at 0.05.  
 
RESULTS 
Comparison of ACE-III performance in patients with EOD and controls 
There were no significant differences in baseline demographics between patients and healthy 
controls (HC) or between the dementia subgroups (see Table-1). SMI was associated with a 
significantly younger age compared to HC and EOD (p<0.0001) but there were no significant 
differences in sex distribution or education.  
There was no significant correlation between ACE-III scores in EOD and disease duration or 
age. A ROC curve analyses suggested a cut-off score of 88/100 as optimum to distinguish 
patients from controls. This cut-off identified EOD with a sensitivity of 91.5% and a 
specificity of 96.4%. On considering individual subgroups, the lowest sensitivity was 
observed in bvFTD (83.3%), while values in the other dementia syndromes exceeded 90% 
(AD 96.8%, 90.9% for PPA and PCA).  
 
Mean total ACE-III score and sub-scores on all domains were significantly higher in HC 
compared to EOD (p<0.0001 in all cases, details provided in Table-2). Post-hoc analyses 
revealed significant differences between HC and all four EOD subgroups in memory 
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(p<0.0001), fluency (p<0.0001) and language (p≤0.023). Significant differences in attention 
sub-scores were observed between HC and AD, PCA, PPA (p≤0.001) but not bvFTD 
(p=0.125).Only AD and PCA had significantly lower mean visuospatial sub-scores compared 
to HC (p<0.0001 in both cases).   
SMI was associated with significantly lower total ACE-III, fluency and memory sub-scores 
compared to HC (p≤0.014, see Table-2). However, ACE-III total score and all sub-scores 
were significantly higher in SMI compared to EOD (p≤0.002 in all cases). A total ACE-III 
score of 88/100 distinguished EOD from SMI with high sensitivity (91.5%) and specificity 
(86.7%).  
  
Within-EOD Group Differences  
Significant inter-group differences among the EOD subgroups were observed for mean 
attention (p=0.014), memory (p=0.030) and visuospatial (p<0.0001) sub-scores. On post-hoc 
analyses, AD was associated with significantly lower mean scores for attention (p=0.017) 
and memory (p=0.026) compared to bvFTD. PCA was associated with significantly lower 
mean visuospatial sub-scores compared to other three sub-groups (p<0.0001 in all cases).  
Figure 2 illustrates the proportion of patients in each dementia subgroup with impaired 
performance (a score that is two standard deviations below the HC mean) in the different 
ACE-III domains. Significant within-EOD group differences in rates of impairment were 
observed in visuospatial skills (p=0.004) and in memory (p=0.003). The difference in rates 
of poor performance in  visuo-spatial domain were driven by significantly higher rates in the 
PCA group compared to FTD and PPA (p≤0.0008),  while that in the  memory domain  was 
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driven  by significant higher rates of memory impairment in AD compared to bvFTD 
(p=0.001).  
DISCUSSION  
This study based on a heterogeneous ‘real life’ EOD clinic population suggests the ACE-III is 
a reliable tool for screening for cognitive decline. The test takes approximately 15 minutes to 
undertake, differentiates EOD from healthy controls with high specificity and sensitivity, 
suggesting that it is an effective tool for screening for dementia.  
The ACE-III also differentiated EOD patients from individuals with SMI. The younger age of 
individuals with SMI compared to EOD patients is most likely a reflection of the increasing 
risk of dementia with age. In addition, our definition of SMI included lack of progression on 
longitudinal follow up. A recent study investigating the predictors of cognitive decline in 
individuals with SMI reported that younger age was associated with reduced risk of 
developing cognitive decline on follow up.10  
The lowest sensitivity was observed in bvFTD with 3/18 patients scoring above the cut-off 
for abnormal performance.  This finding is consistent with current understanding that 
cognitive domains measured using the ACE-III can be intact in early stage bvFTD despite 
marked breakdown in behaviour.11 This highlights the importance of formal evaluation of 
behaviour in suspected bvFTD. In addition, early cognitive changes in bvFTD often affects 
executive functioning, a heterogeneous domain which is difficult to evaluate 
comprehensively. 12,13 Executive function is represented in the ACE-III with a single task 
(verbal fluency), a limitation noted by its authors.4 It is possible that additional impairment 
might be identified in bvFTD using more detailed examination of executive functions, or as 
suggested by some recent reports, using tasks of social cognitive skills.14,15 
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 Whilst the ACE-III differentiated patients with dementia from HC with high sensitivity and 
specificity, there were few significant differences between dementia subgroups. Visuospatial 
performance in PCA was significantly worse than in other dementia syndromes, in line with 
the prominent visuoperceptual deficits in these patients.  
Patients with bvFTD displayed significant dysfunction in memory and language while 
performance on attention was similar to controls in line with previous findings.16 Our 
observation of memory impairment in 60% of patients with bvFTD is also consistent with 
reports suggesting memory impairment is common in early-onset FTD.17 However, both 
mean memory scores and rates of memory impairment were significantly worse in AD. 
Conversely, there were no significant differences between bvFTD and AD in performance on 
verbal fluency, a task where poor performance is classically associated with bvFTD. All 
dementia subgroups performed poorly on this task with no significant inter-group differences.  
The verbal fluency task is a complex task which places heavy demands on multiple fronto-
striatal circuits, language production, and word retrieval functions. The integrity of these 
systems can be affected by pathology at multiple anatomical sites,13,18 reducing the specificity 
of the task. In addition, the ACE-III is combines both letter and category fluency increasing 
the sensitivity of the task to a wide range of dementia syndromes.19,20  
 
An unexpected finding was the lack of significant between-group differences in language 
performance. This contrasted with the ACE-III validation study where the only reported 
significant difference between dementia groups was in the language domain, with lower 
scores in PPA compared to bvFTD and AD.4  Our results may be related to sample size or to 
differences in phenotypic expression in EOD. Non-amnestic variants have been reported 
more frequently in early-onset AD patients compared to late-onset disease.21 It is conceivable 
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that subtle language impairment is more common in early-onset AD, and possibly bvFTD. 
The poor performance in the PCA group probably reflects the heavy reliance of the ACE-III 
language subtasks (e.g. object naming, reading) on intact visuospatial perception. Similarly, 
poor memory scores in PPA are likely to be at least partially influenced by the verbal nature 
of the memory sub-tasks in the ACE-III.  
 
 
The main limitations of this study are its retrospective design, the use of a convenience 
sample of consecutive patients attending a tertiary memory clinic, and lack of pathological 
confirmation of final diagnoses. In addition, the study may be under-powered for small sized 
effects between diagnostic sub-groups. Further large scale, prospective studies would be ideal 
to confirm our findings.  
 
Our findings, based on a heterogeneous clinic cohort, suggest that, notwithstanding its 
limitations, the ACE-III is a reliable tool for screening for cognitive decline in EOD. 
However, we would recommend that clinicians should use the ACE-III as a diagnostic 
adjunct and should consider, in the appropriate clinical context, the inclusion of a behavioural 
questionnaire and/or additional tasks of executive and language function.  
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FIGURE LEGEND 
 
Figure 1. This figure illustrates the rates of abnormal performance on the different 
ACE-III domains in healthy controls, individuals with subjective memory impairment, 
and patients with early onset dementia. Key: AD: Alzheimer’s disease; bvFTD: 
behavioural variant frontotemporal dementia, PPA: primary progressive aphasia; 
PCA: Posterior cortical atrophy; HC: Healthy controls; SMI subjective memory 
impairment.  
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Table 1 This table provides a summary of the basic characteristics of the EOD subgroups and those of controls. Key AD: Alzheimer’s disease; bvFTD: behavioural variant 
frontotemporal dementia, PPA: primary progressive aphasia; PCA: Posterior cortical atrophy; HC: Healthy controls; SMI subjective memory impairment; P1 refers to p value 
obtained on one-way ANOVA comparing healthy controls to patients with dementia; P2 refers to p value obtained on within group comparisons of the 4 dementia groups. P3 
refers to p value obtained on comparing HC to individuals with subjective memory impairment.  
 
 AD n bvFTD n PPA n PCA n SMI n HC  n P1 P2 P3 
Mean Age at Testing yrs (SD) 62.6 (5.3) 31 63.6 (4.9) 18 62.2 (5.4) 11 61.1 (5.3) 11 54.0 (6.3) 15 66.6 (8.6) 28 0.065 0.643 <0.000 
Males % 48.4% 31 44.4% 18 72.7% 11 18.2% 11 60.0% 15 57.1% 28 0.110 0.083 0.977 
Median Disease duration (yrs)  2.0 31 4.0 17 4.0 11 4.0 11 - -    0.243 0.243 
Education  
           < 16 years  
 
46.7% 
 
30 
 
27.8% 
 
18 
 
27.3% 
 
11 
 
36.4% 
 
11 
 
26.7% 
 
15 
 
53.6% 
 
28 
 
 
 
 
         16-18 years  26.7%  44.4%  72.7%  45.5%  46.7%  42.9%  0.179 0.362 0.059 
         >18 years  16.7%  27.8%  0.0%  18.2%  26.7%  3.6%     
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Table 2 This table provides a summary of the mean scores of the EOD subgroups and those of controls. Standard deviations are shown in parenthesis. Key AD: Alzheimer’s 
disease; bvFTD: behavioural variant frontotemporal dementia, PPA: primary progressive aphasia; PCA: Posterior cortical atrophy; HC: Healthy controls; SMI subjective 
memory impairment; P1 refers to p value obtained on one-way ANOVA comparing healthy controls to patients with dementia; P2 refers to p value obtained on within group 
comparisons of the four dementia groups. P3 refers to p value obtained on comparing HC to individuals with subjective memory impairment.  
 
 AD bvFTD PPA PCA SMI HC P1 P2 P3 
Total ACEIII (max100) 61.0 (17.0) 72.5(3.1) 61.3(23.7) 59.6 (15.4) 92.3 (3.7) 96.7(3.4) <0.0001 0.104 0.001 
Attention (max18) 11.9 (4.2) 15.4 (2.4) 13.4 (5.0) 11.7 (2.6) 17.5 (0.6) 17.8(0.5) <0.0001 0.014 0.107 
Memory  (max24) 11.5 (5.0) 16.1 (6.7) 11.1 (6.1) 14.7 (6.1) 23.3 (1.8) 24.8(2.2) <0.0001 0.030 0.003 
Fluency (max14) 5.8 (3.2) 5.2 (3.0) 5.5 (4.1) 6.8 (3.8) 11.4 (2.0) 13.0(1.3) <0.0001 0.676 0.014 
Language (max26) 20.5 (4.0) 21.1 (5.8) 18.7 (7.0) 21.1 (2.3) 25.5 (0.7) 25.7(0.7) <0.0001 0.599 0.168 
Visuo-spatial skills (max16) 11.3 (4.1) 13.6 (2.8) 13.0 (3.4) 4.9 (3.0) 15.6 (0.7) 15.5(0.8) <0.0001 <0.0001 0.820 
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